Australia's mesothelioma guidelines have been updated, reflecting major advances in pathology, immunotherapy, and multidisciplinary care. The new guidelines, developed by the Australian Data and Digital Research Institute (ADDRI) with support from various agencies, offer a more comprehensive and personalized approach to treating this incurable disease. The update is particularly significant given the high incidence of mesothelioma in Australia, largely due to past asbestos use. The guidelines emphasize the importance of early diagnosis and multidisciplinary care, incorporating modern immunohistochemistry and molecular testing into routine assessment. Treatment recommendations have been revised to include immunotherapy as a standard first-line option, while chemotherapy remains appropriate for selected patients. The guidelines also stress the need for supportive care, including palliative care from diagnosis, and address inequities in care by promoting telehealth and virtual multidisciplinary meetings for patients in regional and remote areas. However, the report highlights the need for further research and education to improve patient outcomes, as the incidence of mesothelioma is predicted to remain high for the foreseeable future.
